Status:
TERMINATED
Dose Escalation of IPI-493 in Hematologic Malignancies
Lead Sponsor:
Infinity Pharmaceuticals, Inc.
Conditions:
Hematologic Malignancies
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.
Eligibility Criteria
Inclusion
- \>/=18 years old
- ECOG 0-1
- confirmed hematological malignancy
- refractory to available therapy or for which no therapy is available
- adequate hepatic, renal function
Exclusion
- active CNS malignancy
- prolonged QT interval
- significant GI/liver disease
- other serious concurrent illness or medical condition
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01193491
Start Date
June 1 2010
End Date
July 1 2011
Last Update
April 15 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Sidney Kimmel Cancer Center
Baltimore, Maryland, United States, 21201
2
Weill Cornell Cancer Center
New York, New York, United States, 10065
3
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030